OutSee, a genomics and drug discovery company developing an AI-based predictive genomics platform, has closed a £2.5 million seed funding round and signed a strategic collaboration with o2h discovery, a preclinical contract research organisation. The partnership will support a joint drug discovery programme focused on OutSee’s lead target candidate, identified using its proprietary Nomaly precision medicine platform.
The seed round was led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors. The funding completes a first close announced in June 2025 and will be used to advance experimental validation of multiple AI-identified targets while continuing development of the Nomaly platform.
Founded by Dr Julian Gough, OutSee applies AI-driven, hypothesis-free genomic modelling to predict disease mechanisms directly from genomic data. The collaboration with o2h discovery, supported through the InflexionTx co-discovery model, will build a library of drug candidates and accelerate translation from target discovery into therapeutic development.
Featured image: Credit: OutSee
